Abstract
Gliomas are the most prevalent form of primary malignant brain tumor, which currently have no effective treatments. Evidence from human studies has indicated that oral microbiota is closely related to cancers; however, whether oral microbiota plays a role in glioma malignancy remains unclear. The present study aimed to investigate the association between oral microbiota and grade of glioma and examine the relationship between malignancy-related oral microbial features and the isocitrate dehydrogenase 1 (IDH1) mutation in glioma. High-grade glioma (HGG; n=23) patients, low-grade glioma (LGG; n=12) patients, and healthy control (HCs; n=24) participants were recruited for this case-control study. Saliva samples were collected and analyzed for 16S ribosomal RNA (rRNA) sequencing. We found that the shift in oral microbiota β-diversity was associated with high-grade glioma (p=0.01). The phylum Patescibacteria was inversely associated with glioma grade (LGG and HC: p=0.035; HGG and HC: p<0.01). The genera Capnocytophaga (LGG and HC: p=0.043; HGG and HC: p<0.01) and Leptotrichia (LGG and HC: p=0.044; HGG and HC: p<0.01) were inversely associated with glioma grades. The genera Bergeyella and Capnocytophaga were significantly more positively correlated with the IDH1 mutation in gliomas when compared with the IDH1-wild-type group. We further identified five oral microbial features (Capnocytophaga Porphyromonas, Haemophilus, Leptotrichia, and TM7x) that accurately discriminated HGG from LGG (area under the curve [AUC]: 0.63, 95% confidence interval [CI]: 0.44–0.83) and HCs (AUC: 0.79, 95% CI: 0.68–0.92). The functional prediction analysis of oral bacterial communities showed that genes involved in cell adhesion molecules (p<0.001), extracellular matrix molecule-receptor interaction (p<0.001), focal adhesion (p<0.001), and regulation of actin cytoskeleton (p<0.001) were associated with glioma grades, and some microbial gene functions involving lipid metabolism and the adenosine 5'-monophosphate-activated protein kinase signaling pathway were significantly more enriched in IDH1 mutant gliomas than compared with the IDH1-wild-type gliomas. In conclusion, our work revealed oral microbiota features and gene functions that were associated with glioma malignancy and the IDH1 mutation in glioma.
Keywords: glioma, malignant grade, oral microbiota, isocitrate dehydrogenase 1 mutation, human cohort
Introduction
Gliomas, the most common primary tumor of the central nervous system, are stratified into grades 1–4 based on the histological features defined by the World Health Organization (WHO; Louis et al., 2016). This classification system has been transformed into a molecular feature-based classification system and can be used for the formulation of targeted therapeutic methods, which have been shown to have a higher level of prognostic accuracy (Louis et al., 2016, 2020; Brat et al., 2020). WHO grades 1–2 gliomas (low-grade gliomas; LGG) exhibit low aggressive tendencies and have a better prognosis, whereas WHO grades 3–4 gliomas (high-grade gliomas; HGG) have a high rate of deterioration and a poor prognosis (Louis et al., 2016). Evidence from human studies has indicated that oral microbiota is closely related to cancers (Michaud et al., 2013; Fan et al., 2018); however, whether oral microbiota plays a role in glioma malignancy remains unclear.
The presence of mutant forms of isocitrate dehydrogenase 1 (IDH1) is a key factor in determining the prognosis of patients with gliomas. Generally speaking, glioma patients with the IDH1 mutation have a more favorable prognosis, and the mutation is frequently expressed in patients with an LGG but rarely detected in patients with a WHO grade 4 glioma (Ceccarelli et al., 2016). Oral microbial-produced substances may be carcinogenic (Kurkivuori et al., 2007; Meurman and Uittamo, 2008). Therefore, the mechanism underlying the link between the IDH1 mutation and better prognosis may involve the variation in the composition and function of oral microbiota. Currently, the relationship between oral microbiota and the glioma IDH1 mutation is uncertain.
Therefore, we aimed to investigate the association between oral microbiota and glioma grade and examine the relationship between the composition and functional features of malignancy-related oral microbiota and the glioma IDH1 mutation.
Materials and Methods
Study Subjects and Study Design
The cohort was a prospective cohort that included 59 participants of Han Chinese ethnicity. This study was a cross-sectional analysis of the retrospective cohort at baseline. Briefly, 59 participants aged 20–74years who were living in Luzhou City, Southern China, were recruited by the Department of Neurosurgery, Affiliated Hospital of Southwest Medical University, between April 2019 and October 2020. We collected sociodemographic, lifestyle, and dietary factor information. Anthropometric parameters, which included weight and height, were measured by trained nurses. The glioma IDH1 mutation was assessed by postoperative pathological diagnosis. Clinical physiological variables (blood glucose value) were measured using a blood glucose monitor. Oral saliva samples of participants were collected during participants’ visits to the study site. We excluded participants who had been physiologically diagnosed with a non-glioma and had not received surgery. Finally, 59 participants were included in the present analysis (see inclusion and exclusion criteria for further details; Supplementary Methods; Supplementary Figure 1).
Glioma grades were assessed according to the 2016 WHO Classification of Tumors of the Central Nervous System. Participants were divided into three groups: (i) healthy controls (HCs; n=24), (ii) LGG group (n=12), and (iii) HGG group (n=23) according to the criteria for glioma grades. HCs were recruited from patients’ families, such as their spouses and parents. The study protocol was approved by the ethics committee of the Affiliated Hospital of Southwest Medical University (No. KY2019030), and all participants provided written informed consent.
Sample Collection and DNA Extraction
Participants were asked to refrain from drinking, eating, brushing teeth, or smoking on the morning of the study visit and to rinse out impurities in the mouth with sterile saline. During the visit to the study center, participants were provided with a saliva sampler and detailed instructions for the saliva sample collection. Briefly, each participant collected their saliva sample by natural secretion, which was kept in the mouth for 3min. They then spat 20ml of saliva into a 50-ml sterile centrifugal tube. All saliva samples were immediately frozen and stored in a −80°C freezer.
All DNA extraction steps were performed in a biosafety cabinet. Oral saliva DNA was isolated using a QIAamp Fast DNA Stool Mini Kit (QIAGEN, Hilden, Germany) according to standard protocols. NanoDrop was used to quantitatively detect the concentration of DNA in each sample, and 1% agarose gel electrophoresis was used to evaluate the integrity of DNA. The DNA samples that met the quality requirements (i.e., A260/280=1.8–2.8, total DNA>500ng, the main strip of the gel was complete without an obvious tail) were frozen at −80°C for subsequent analyses, and non-conforming samples were discarded.
Oral Microbiota Profiling Using 16S rRNA Sequencing
The 16S ribosomal RNA (rRNA) gene amplification procedure was divided into two polymerase chain reaction (PCR) steps. For the first PCR reaction, the V3-V4 hypervariable region of the 16S rRNA gene was amplified from the genomic DNA using primers 338F(ACTCCTACGGGAGGCAGCAG) and 806R(GGACTACHVGGGTWTCTAAT). The amplification products were purified by gel extraction (AxyPrep DNA Gel Extraction Kit, Axygen Biosciences, Union City, CA, United States) according to manufacturer instructions. The concentration of the pooled libraries was determined using the Qubit quantification system. Amplicon sequencing was performed on the MiSeq PE250 platform (Illumina, San Diego, California, United States). Automated cluster generation and 2×250bp paired-end sequencing with dual-index reads were performed.
16S rRNA Gene Sequencing Bioinformatics Analysis
Sequence analysis was performed using the Quantitative Insights into Microbial Ecology Pipeline (QIIME) software version 2-2020.2 (Bolyen et al., 2019). The divisive amplicon denoising algorithm (DADA2; Callahan et al., 2016) was used for amplicon sequence variant (ASV) clustering equaling 100%. A representative sequence was selected for each ASV, and the SILVA reference database was used to annotate taxonomic information. The absolute abundance table was extracted from the pipeline and converted into relative abundances by normalization for analyzing the composition of gut microbiota by QIIME2 for downstream analysis.
Statistical Analyses
For comparisons between the three groups, we used the chi-square test for categorical variables and analysis of variance (ANOVA) for continuous variables. We examined the associations between glioma grade and oral microbial α-diversity indices (Shannon, ACE, and Chao1 indices and Good’s coverage), which were estimated based on species richness in the ASV subsample table. The association between glioma grade and β-diversity (between-subject diversity) dissimilarity, based on ASV-level Bray-Curtis distance, was analyzed using permutational ANOVA (999 permutations), adjusted for age, sex, and body mass index (BMI).
We used Wilcoxon rank-sum tests to determine oral microbiota and microbial function associations with glioma grade (a value of p≤0.05 was considered statistically significant). The Benjamini-Hochberg method was used to control for false discovery rate (FDR). Receiver operator characteristic curves based on the identified oral microbial features were used to discriminate different glioma grade patients from HCs. The true positive rate (sensitivity) was plotted against the false positive rate (100%−specificity), and the area under the curve (AUC) values were reported with 95% confidence intervals (CI) as an estimate of diagnostic utility.
We examined the associations between the composition and functional features of malignancy-related oral microbiota and the glioma IDH1 mutation using multivariable linear regression, adjusted for age, sex, and BMI. The Benjamini-Hochberg method was used to control for FDR. We also conducted stratified analyses for smoking and alcohol status. Analyses were carried out using R statistical software (version 3.3.1, R Foundation). A value of p <0.05 was considered statistically significant.
Results
Characteristics of Study Participants
The demographic characteristics of participants are shown in Table 1. The mean (standard deviation) age was 46.12 (12.69) years, and 47.46% were women (Table 1).
Table 1.
Characteristics | HCs (N=24) | Glioma grade | |||
---|---|---|---|---|---|
LGG (N=12) | HGG (N=23) | ||||
Age (years) | |||||
Range | 32–57 | 20–61 | 21–74 | ||
Mean±SD | 45.29±6.72 | 37.67±13.49 | 51.39±14.75 | ||
Gender | |||||
Male | 10 (41.67%) | 8 (66.67%) | 13 (56.52%) | ||
Female | 14 (58.33%) | 4 (33.33%) | 10 (43.48%) | ||
BMI (kg/m2) | |||||
Range | 19.59–37.78 | 18.51–25.77 | 18.07–28.69 | ||
Mean±SD | 25.59±3.42 | 22.18±1.90 | 22.99±2.90 | ||
Blood glucose | |||||
Range | — | 4.4–14.9 | 4.77–22.5 | ||
Mean±SD | — | 7.0±3.06 | 8.13±3.63 | ||
Excrement regularity | |||||
Yes | 17 (70.83%) | 9 (75%) | 16 (69.57%) | ||
No | 7 (29.17%) | 3 (25%) | 7 (30.43%) | ||
Brushing habits | |||||
Numbers | 0 time | 0 (0%) | 3 (25%) | 3 (13.05%) | |
1 time | 20 (83.33%) | 7 (58.33%) | 13 (56.52%) | ||
2 times | 4 (16.67%) | 2 (16.67%) | 7 (30.43%) | ||
Time | <2min | 21 (87.5%) | 6 (50%) | 22 (95.65%) | |
> 2min | 3 (12.5%) | 6 (50%) | 1 (4.35%) | ||
Tooth missing | |||||
Yes | 7 (29.17%) | 5 (41.67%) | 9 (39.13%) | ||
No | 17 (70.83%) | 7 (58.33%) | 14 (60.87%) |
In this study, according to the recruitment standard, 59 cases including 24 HCs and 35 glioma patients were included. Glioma patients were divided into LGG (N=12), HGG (N=23). HCs, healthy controls; LGG, low-grade glioma; HGG, high-grade glioma.
Association Between Glioma Grade and Oral Microbiota Diversity
We first investigated the associations between glioma grade and microbiome α-/β-diversity. A significant difference in microbial β-diversity (p=0.01) was found between the HGG and HC groups (Figure 1A), whereas no significant difference was found between the LGG and HC groups (p=0.51; Figure 1B), and no significant difference was found between the LGG and HGG groups (p=0.89; Figure 1C). There were no significant differences in measures of α-diversity between the glioma groups and the HCs [HGG and HC: Shannon index: p=0.34, phylogenetic diversity (PD): p=0.86; LGG and HC: Shannon index: p=0.91, PD: p=0.21].
Glioma Grades Were Associated With Oral Microbiota Composition and Gene Function
Our results showed that 99.57% of the oral microbiota was aligned to seven phyla, which included Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria, Patescibacteria, and Spirochaetota (Figures 2A,B). The abundance of Patescibacteria decreased significantly with increasing malignancy of glioma from LGG (p=0.035) to HGG (p<0.01), compared with HCs (Figure 3A). The proportions of the other six phyla (Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria, and Spirochaetota) were not associated with glioma grade (Supplementary Figure 2).
The ASVs were assigned to 181 individual genera of which 18 were present in all samples with a relative abundance of more than 1% in at least one sample (Supplementary Figures 3A,B). The genera Capnocytophaga (LGG and HC: p=0.043; HGG and HC: p<0.01) and Leptotrichia (LGG and HC: p=0.044; HGG and HC: p<0.01) were inversely associated with glioma grade (Figure 3B). Five oral microbial features [Porphyromonas (p<0.05), Haemophilus, Leptotrichia (p<0.05), TM7x (p<0.05), and Capnocytophaga (p<0.05)] were significantly lower in the HGG group compared with the HC group (Figure 3C). The five oral microbial features (Porphyromonas, Haemophilus, Leptotrichia, TM7x, and Capnocytophaga) accurately discriminated the HGG group from HCs (AUC: 0.79, 95% CI: 0.68–0.92; Figure 4 and Supplementary Table 1). We also use bacterial marker panels to discriminate the HGG group from the LGG group (AUC: 0.63, 95% CI: 0.44–0.83) and the LGG group from HCs (AUC: 0.57, 95% CI: 0.36–0.78; Figure 4).
We used the Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) to predict the oral microbiome functions via the saliva microbiome data sets. Signaling molecules and interactions, such as cell adhesion molecules (CAMs), extracellular matrix (ECM)-receptor interactions, cellular community-eukaryotes (focal adhesion), and actin cytoskeleton regulation, were positively associated with glioma grade, while the polycyclic aromatic hydrocarbon degradation and the Bile secretion were inversely associated with HCs (Figure 5).
Glioma IDH1 Mutation Was Associated With Malignancy-Related Oral Microbiota and Gene Function
Results showed that the abundance of Firmicutes was significantly lower in the IDH-mutant samples compared with that of the IDH-wild-type samples at the phylum level (Figure 6A). The genus-level profiling showed that the abundance of Bergeyella and Capnocytophaga was significantly positively correlated with the IDH-mutant samples (Figure 6B). We also used PICRUSt to predict Kyoto Encyclopedia of Genes and Genomes (KEGG)-based functional orthologs between the IDH-mutant and IDH-wild-type groups to characterize the functional alterations, which were inferred from the 16S rRNA gene sequencing data. We found 82 pathways that were significantly greater in the IDH-mutant group compared with those of the IDH-wild-type group using the Mann-Whitney U test. Our result revealed that several metabolic-related pathways, such as lipid metabolism (linoleic acid, ether lipid metabolism, fatty acid biosynthesis, glycerophospholipid, and biosynthesis of unsaturated fatty acids), fatty acid metabolism (alpha-linolenic acid), amino acid metabolism (tyrosine metabolism, tryptophan metabolism, lysine degradation, and glycine, serine, and threonine metabolism), carbohydrate metabolism (inositol phosphate metabolism), and cofactors and vitamin metabolism (retinol metabolism), were significantly higher in the IDH-mutant group compared with those of the IDH-wild-type group. Moreover, signal transduction, such as the adenosine 5′-monophosphate-activated protein kinase (AMPK) signaling pathway, the phosphatidylinositol signaling system, the sphingolipid signaling pathway, and the phospholipase D signaling pathway, was more enriched in the IDH-mutant group than in the IDH-wild-type group (Supplementary Figure 4).
Discussion
To our knowledge, this is the first comprehensive clinical 16S rRNA sequencing data set to characterize the community features of oral microbiota in different glioma grades. We found that the shift in oral microbiota β-diversity was associated with HGG. The phylum Patescibacteria was inversely associated with glioma grade, and the genera Capnocytophaga and Leptotrichia were inversely associated with glioma grade. We identified five oral microbial features (Porphyromonas, Haemophilus, Leptotrichia, TM7x, and Capnocytophaga) that accurately discriminated patients with HGG from those with LGG and HCs. The gene function of oral bacterial communities was associated with glioma grade. Moreover, the abundance of the phylum Firmicutes was significantly negatively correlated with IDH-mutant samples, whereas the genera Bergeyella and Capnocytophaga were significantly positively correlated with IDH-mutant samples. Several microbial (lipid metabolism, amino acid metabolism, and energy metabolism) and signal transduction (AMPK signaling pathway) pathways were significantly higher in the glioma IDH-mutant group than those in the glioma IDH-wild-type group. Our findings revealed that oral microbiota features and gene functions are associated with glioma malignancy and the IDH1 mutation.
Previous studies have shown that oral microbiome significantly affected the composition of gut microbiome (Hou et al., 2021; Pandya et al., 2021; Park et al., 2021). The oral microbiome and gut microbiome can spread to the brain through cranial nerves or cellular infections or produced certain metabolites to affect the brain by both direct and indirect means (Dominy et al., 2019; Jing et al., 2021; Narengaowa et al., 2021; Vyhnalova et al., 2021; Wang et al., 2021). Our results showed significant differences in oral microflora between HGG patients and HCs; oral Patescibacteria was significantly decreasing during the progression of glioma malignancy. Few studies have reported a correlation between oral Patescibacteria and human disease. This is the first study examining Patescibacteria in oral saliva samples of glioma patients and suggests Patescibacteria as a negatively associated risk factor for disease progression from LGG to HGG. Our results highlight the potential of Patescibacteria detection as a diagnostic and prognostic determinant for glioma malignancy, but further experimental research to establish the mechanistic basis of these relationships is needed.
In addition, the phylum Fusobacteriota was significantly lower in the HGG group than in the HCs. Furthermore, the family Leptotrichiaceae (Supplementary Figure 3C) and the genus Leptotrichia, which belongs to Fusobacteriota, were inversely associated with glioma malignancy. This is consistent with the results of two large, nested, case-control studies in which a greater abundance of Leptotrichia was associated with a decreased risk of pancreatic cancer (Michaud et al., 2013; Fan et al., 2018). Leptotrichia is considered an opportunistic pathogen and can stimulate human immune system responses (Eribe and Olsen, 2017). Moreover, Leptotrichia may elicit the immune response and thus protect against pancreatic carcinogenesis (Inman et al., 2014).
Genus-level analysis showed that a bacterial marker panel with Capnocytophaga, TM7x, Porphyromonas, Haemophilus, and Leptotrichia had an AUC of 0.79 for discriminating between HGG and HCs. We found that the relative abundance of genus Capnocytophaga was inversely associated with glioma malignancy. Capnocytophaga is a genus of Gram-negative anaerobes that inhabit the oral cavity (Lopez et al., 2010), which has been reported to be inversely associated with human diseases, such as chorioamnionitis, neonatal infection (Lopez et al., 2010), and lung cancer (Thirumala et al., 2012). Consistent with our results, Hayes et al. reported that a greater abundance of the genus Capnocytophaga was significantly associated with a reduced risk of larynx cancer (Hayes et al., 2018). However, the protective mechanism of Capnocytophaga for glioma malignancy remains unclear. Previous studies have consistently shown a decrease in Haemophilus and Porphyromonas in the saliva of patients with cancer compared with that of HCs (Mei et al., 2018; Yang et al., 2018; Lu et al., 2019; Li et al., 2020). In addition, the high abundance of Haemophilus and Porphyromonas is associated with anticancer-associated immunity (Lu et al., 2019). A high level of antibodies to Porphyromonas gingivalis in the serum correlates with a lower risk of pancreatic cancer (Michaud et al., 2013). This study is the first to report the inverse association between the abundance of TM7x and glioma malignancy and that TM7x is a useful bacteria marker for glioma malignancy diagnosis.
The functional prediction showed that environmental information processing, such as CAMs and ECM-receptor interactions, was significantly higher in HGG patients than in the HCs. Several CAMs, such as neural cell adhesion molecule L1, have been identified to underlie the occurrence of glioma malignancies (Senner et al., 2002; Jiang et al., 2019; Lyu et al., 2021). ECM plays an important role in gliomas, such as in the higher expression of laminin a2 in glioblastoma (Lathia et al., 2012). The key role of the focal adhesion pathway and the level of actin in the cytoskeleton during the migration and invasion of glioblastoma have also been reported (de Semir et al., 2020; Wu et al., 2020).
Our results demonstrated that the genera Bergeyella and Capnocytophaga were significantly positively correlated with the glioma IDH-mutant, which is consistent with the results of glioma malignancy. The IDH1-mutant plays an important role in glioma cell glucose induction, glutamine metabolism, lipid synthesis, and cell redox regulation (Hartmann et al., 2009; Maus and Peters, 2017; Stuani et al., 2018). Moreover, metabolism deregulation plays an important role in cell growth, proliferation, angiogenesis, and invasion; thus, it has been considered one of the emerging hallmarks of cancer cells (Hanahan and Weinberg, 2011). Recent studies have found that lipid metabolism reprogramming plays a crucial role in the progression of cancer cells, such as in membrane synthesis, energetic production, and signal transduction (Liu et al., 2017). The activation of the AMPK signaling pathway contributes to the anti-inflammatory microenvironment of IDH1-mutated gliomas and thus causes better prognoses in patients with an IDH1-mutated glioma (Han et al., 2019). Our results demonstrated that the malignancy inverse-related microbial gene functions involving lipid metabolism and AMPK signaling pathway were significantly enriched in the IDH-mutant group, suggesting that changes in oral microbial gene functions may underlie the link between the positive association between IDH-mutant gliomas and better prognosis. Moreover, several studies reported that mutant IDH1 in gliomas regulated a number of physiological processes such as inflammatory pathways, metabolic metabolism, hypoxia sensing, histone demethylation, and changes in DNA methylation causing DNA strand breaks, apoptosis, autophagy, and tumor cell death (Gilbert et al., 2014; Viswanath et al., 2018; Zhang et al., 2019; Kadiyala et al., 2021; Pirozzi and Yan, 2021). Therefore, the possible mechanism underlying the association between oral microbiome and IDH1 mutation is that IDH1 mutation specifically selects some oral microbiota, which can produce specific metabolites involved in lipid metabolism and AMPK signaling pathway to regulate intracellular energy homeostasis, increase brain glioma cell apoptosis and autophagy, prevent brain glioma cell proliferation, and contribute to the formation of an anti-inflammatory tumor microenvironment in the brain, and further causes better prognoses in patients with an IDH1-mutated glioma. Certainly, animal and cell experiments are further needed to determine the causality of IDH1 mutation on the oral microbiome under glioma status.
The present study has several strengths. First, to the best of our knowledge, this is the first study examining the role of oral microbiota in glioma malignancy. Second, we developed a novel bacterial marker panel to discriminate HGG patients from LGG patients and HCs. Third, our study revealed that the composition and gene function of oral microbiota were significantly associated with the IDH1 mutation in glioma, which can be used to predict the prognosis of glioma patients. The present study also has several limitations. First, the sample size was relatively small. This study was a small-sample, single-center study because of the challenges in recruiting this type of cohort and the strict inclusion criteria. However, this also guaranteed the consistency of the sample. Second, although we demonstrated that oral microbiota was associated with glioma malignancy and the IDH mutation, the underlying causality remains unclear. Finally, no plaque or tongue-coating specimens were included because of the difficulty in collecting such samples.
In summary, the present study indicated that oral microbiota composition and gene functions are significantly associated with glioma malignancy and the IDH1 mutation. We also discovered a microbial biomarker panel to distinguish HGG patients from HCs. Our results suggest that oral microbiota may be an important preventive target to mitigate glioma malignancy and achieve better prognoses for glioma patients.
Data Availability Statement
The data presented in the study are deposited in the National Library of Medicine repository (https://submit.ncbi.nlm.nih.gov/), BioProject accession number: PRJNA750937 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA750937).
Ethics Statement
The studies involving human participants were reviewed and approved by Ethics committee of the Affiliated Hospital of Southwest Medical University (No. KY2019030). The patients/participants provided their written informed consent to participate in this study.
Author Contributions
YW, LC, and JZ conceived the study and designed the experiments. YW, LF, and HW analyzed and interpreted the data. YW, LF, HW, and ZJ generated the figure, drafted the manuscript, and contributed to critical revision of the manuscript. HZ, QL, WZ, and MW visited patients, collected the data, and critical revision of the manuscript. YL and XL collected the samples and critical revision of the manuscript. YW, LF, and HW revised the manuscript with input from JZ and ZJ. LC and JZ obtained funding and contributed to study supervision. All authors contributed to the article and approved the submitted version.
Funding
The research was supported by National Natural Science Foundation project, Grant No. 00022986, and technology projects of Sichuan Province and Grant No. 2018JY0403. The research was further supported by Medical Research Fund for Young Scholars of the Sichuan Medical Association, Grant No. Q16076 and Natural Science Foundation of Southwest Medical University, Grant Nos. 2016XNYD217, 2018-ZRQN-032, and 2016LZXNYD-G03.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
We acknowledge the Shanghai Majorbio Bio-Pharm Technology Co., Ltd. for assistance with MiSeq sequencing.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2021.746568/full#supplementary-material
References
- Bolyen E., Rideout J. R., Dillon M. R., Bokulich N. A., Abnet C. C., Al-Ghalith G. A., et al. (2019). Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 37, 852–857. doi: 10.1038/s41587-019-0209-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brat D. J., Aldape K., Colman H., Figrarella-Branger D., Fuller G. N., Giannini C., et al. (2020). cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 139, 603–608. doi: 10.1007/s00401-020-02127-9, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Callahan B. J., McMurdie P. J., Rosen M. J., Han A. W., Johnson A. J., Holmes S. P. (2016). DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581–583. doi: 10.1038/nmeth.3869 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ceccarelli M., Barthel F. P., Malta T. M., Sabedot T. S., Salama S. R., Murray B. A., et al. (2016). Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse Glioma. Cell 164, 550–563. doi: 10.1016/j.cell.2015.12.028, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Semir D., Bezrookove V., Nosrati M., Scanlon K. R., Singer E., Judkins J., et al. (2020). PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complex. Proc. Natl. Acad. Sci. U. S. A. 117, 9064–9073. doi: 10.1073/pnas.1914505117, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dominy S. S., Lynch C., Ermini F., Benedyk M., Marczyk A., Konradi A., et al. (2019). Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 5:eaau3333. doi: 10.1126/sciadv.aau3333, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eribe E. R. K., Olsen I. (2017). Leptotrichia species in human infections II. J. Oral Microbiol. 9:1368848. doi: 10.1080/20002297.2017.1368848, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fan X., Alekseyenko A. V., Wu J., Peters B. A., Jacobs E. J., Gapstur S. M., et al. (2018). Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut 67, 120–127. doi: 10.1136/gutjnl-2016-312580, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gilbert M. R., Liu Y., Neltner J., Pu H., Morris A., Sunkara M., et al. (2014). Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol. 127, 221–233. doi: 10.1007/s00401-013-1194-6, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Han C. J., Zheng J. Y., Sun L., Yang H. C., Cao Z. Q., Zhang X. H., et al. (2019). The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-kappaB pathway. Acta Pharmacol. Sin. 40, 1292–1302. doi: 10.1038/s41401-019-0225-9, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hanahan D., Weinberg R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646–674. doi: 10.1016/j.cell.2011.02.013, PMID: [DOI] [PubMed] [Google Scholar]
- Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., et al. (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118, 469–474. doi: 10.1007/s00401-009-0561-9, PMID: [DOI] [PubMed] [Google Scholar]
- Hayes R. B., Ahn J., Fan X., Peters B. A., Ma Y., Yang L., et al. (2018). Association of oral microbiome with risk for incident head and neck squamous cell cancer. JAMA Oncol. 4, 358–365. doi: 10.1001/jamaoncol.2017.4777, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hou W., Li J., Cao Z., Lin S., Pan C., Pang Y., et al. (2021). Decorating bacteria with a therapeutic nanocoating for synergistically enhanced biotherapy. Small 17:e2101810. doi: 10.1002/smll.202101810, PMID: [DOI] [PubMed] [Google Scholar]
- Inman K. S., Francis A. A., Murray N. R. (2014). Complex role for the immune system in initiation and progression of pancreatic cancer. World J. Gastroenterol. 20, 11160–11181. doi: 10.3748/wjg.v20.i32.11160, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jiang Q., Xie Q., Hu C., Yang Z., Huang P., Shen H., et al. (2019). Glioma malignancy is linked to interdependent and inverse AMOG and L1 adhesion molecule expression. BMC Cancer 19:911. doi: 10.1186/s12885-019-6091-5, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jing Y., Yu Y., Bai F., Wang L., Yang D., Zhang C., et al. (2021). Effect of fecal microbiota transplantation on neurological restoration in a spinal cord injury mouse model: involvement of brain-gut axis. Microbiome 9:59. doi: 10.1186/s40168-021-01007-y, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kadiyala P., Carney S. V., Gauss J. C., Garcia-Fabiani M. B., Haase S., Alghamri M. S., et al. (2021). Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. J. Clin. Invest. 131:e139542. doi: 10.1172/JCI139542, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kurkivuori J., Salaspuro V., Kaihovaara P., Kari K., Rautemaa R., Gronroos L., et al. (2007). Acetaldehyde production from ethanol by oral streptococci. Oral Oncol. 43, 181–186. doi: 10.1016/j.oraloncology.2006.02.005, PMID: [DOI] [PubMed] [Google Scholar]
- Lathia J. D., Li M., Hall P. E., Gallagher J., Hale J. S., Wu Q., et al. (2012). Laminin alpha 2 enables glioblastoma stem cell growth. Ann. Neurol. 72, 766–778. doi: 10.1002/ana.23674, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li Y., Tan X., Zhao X., Xu Z., Dai W., Duan W., et al. (2020). Composition and function of oral microbiota between gingival squamous cell carcinoma and periodontitis. Oral Oncol. 107:104710. doi: 10.1016/j.oraloncology.2020.104710, PMID: [DOI] [PubMed] [Google Scholar]
- Liu Q., Luo Q., Halim A., Song G. (2017). Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer. Cancer Lett. 401, 39–45. doi: 10.1016/j.canlet.2017.05.002, PMID: [DOI] [PubMed] [Google Scholar]
- Lopez E., Raymond J., Patkai J., El Ayoubi M., Schmitz T., Moriette G., et al. (2010). Capnocytophaga species and preterm birth: case series and review of the literature. Clin. Microbiol. Infect. 16, 1539–1543. doi: 10.1111/j.1469-0691.2010.03151.x, PMID: [DOI] [PubMed] [Google Scholar]
- Louis D. N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W. K., et al. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803–820. doi: 10.1007/s00401-016-1545-1, PMID: [DOI] [PubMed] [Google Scholar]
- Louis D. N., Wesseling P., Aldape K., Brat D. J., Capper D., Cree I. A., et al. (2020). cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 30, 844–856. doi: 10.1111/bpa.12832, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lu H., Ren Z., Li A., Li J., Xu S., Zhang H., et al. (2019). Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls. J. Oral Microbiol. 11:1563409. doi: 10.1080/20002297.2018.1563409, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lyu Y., Yang H., Chen L. (2021). Metabolic regulation on the immune environment of glioma through gut microbiota. Semin. Cancer Biol. doi: 10.1016/j.semcancer.2021.05.005, PMID: [Epub ahead of print] [DOI] [PubMed]
- Maus A., Peters G. J. (2017). Glutamate and alpha-ketoglutarate: key players in glioma metabolism. Amino Acids 49, 21–32. doi: 10.1007/s00726-016-2342-9, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mei Q. X., Huang C. L., Luo S. Z., Zhang X. M., Zeng Y., Lu Y. Y. (2018). Characterization of the duodenal bacterial microbiota in patients with pancreatic head cancer vs. healthy controls. Pancreatology 18, 438–445. doi: 10.1016/j.pan.2018.03.005, PMID: [DOI] [PubMed] [Google Scholar]
- Meurman J. H., Uittamo J. (2008). Oral micro-organisms in the etiology of cancer. Acta Odontol. Scand. 66, 321–326. doi: 10.1080/00016350802446527, PMID: [DOI] [PubMed] [Google Scholar]
- Michaud D. S., Izard J., Wilhelm-Benartzi C. S., You D. H., Grote V. A., Tjonneland A., et al. (2013). Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut 62, 1764–1770. doi: 10.1136/gutjnl-2012-303006, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Narengaowa, Kong W., Lan F., Awan U. F., Qing H., Ni J. (2021). The Oral-gut-brain AXIS: the influence of microbes in Alzheimer’s disease. Front. Cell. Neurosci. 15:633735. doi: 10.3389/fncel.2021.633735, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pandya G., Kirtonia A., Singh A., Goel A., Mohan C. D., Rangappa K. S., et al. (2021). A comprehensive review of the multifaceted role of the microbiota in human pancreatic carcinoma. Semin. Cancer Biol. doi: 10.1016/j.semcancer.2021.05.027, PMID: [Epub ahead of print] [DOI] [PubMed]
- Park S. Y., Hwang B. O., Lim M., Ok S. H., Lee S. K., Chun K. S., et al. (2021). Oral-gut microbiome axis in gastrointestinal disease and cancer. Cancers 13:2124. doi: 10.3390/cancers13092124, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pirozzi C. J., Yan H. (2021). The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 18, 645–661. doi: 10.1038/s41571-021-00521-0, PMID: [DOI] [PubMed] [Google Scholar]
- Senner V., Kismann E., Puttmann S., Hoess N., Baur I., Paulus W. (2002). L1 expressed by glioma cells promotes adhesion but not migration. Glia 38, 146–154. doi: 10.1002/glia.10058, PMID: [DOI] [PubMed] [Google Scholar]
- Stuani L., Riols F., Millard P., Sabatier M., Batut A., Saland E., et al. (2018). Stable isotope labeling highlights enhanced fatty acid and lipid metabolism in human acute myeloid Leukemia. Int. J. Mol. Sci. 19:3325. doi: 10.3390/ijms19113325, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thirumala R., Rappo U., Babady N. E., Kamboj M., Chawla M. (2012). Capnocytophaga lung abscess in a patient with metastatic neuroendocrine tumor. J. Clin. Microbiol. 50, 204–207. doi: 10.1128/JCM.05306-11, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Viswanath P., Radoul M., Izquierdo-Garcia J. L., Ong W. Q., Luchman H. A., Cairncross J. G., et al. (2018). 2-Hydroxyglutarate-mediated autophagy of the endoplasmic reticulum leads to an unusual downregulation of phospholipid biosynthesis in mutant IDH1 Gliomas. Cancer Res. 78, 2290–2304. doi: 10.1158/0008-5472.CAN-17-2926, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vyhnalova T., Danek Z., Gachova D., Linhartova P. B. (2021). The role of the oral microbiota in the etiopathogenesis of oral squamous cell carcinoma. Microorganisms 9:1549. doi: 10.3390/microorganisms9081549, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang Y., Tong Q., Ma S. R., Zhao Z. X., Pan L. B., Cong L., et al. (2021). Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota. Signal Transduct. Target. Ther. 6:77. doi: 10.1038/s41392-020-00456-5, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wu S., Qiao Q., Li G. (2020). A radiosensitivity gene signature and XPO1 predict clinical outcomes for Glioma patients. Front. Oncol. 10:871. doi: 10.3389/fonc.2020.00871, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yang C. Y., Yeh Y. M., Yu H. Y., Chin C. Y., Hsu C. W., Liu H., et al. (2018). Oral microbiota community dynamics associated with oral squamous cell carcinoma staging. Front. Microbiol. 9:862. doi: 10.3389/fmicb.2018.00862, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang Y., Pusch S., Innes J., Sidlauskas K., Ellis M., Lau J., et al. (2019). Mutant IDH sensitizes Gliomas to endoplasmic reticulum stress and triggers apoptosis via miR-183-mediated inhibition of Semaphorin 3E. Cancer Res. 79, 4994–5007. doi: 10.1158/0008-5472.CAN-19-0054, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data presented in the study are deposited in the National Library of Medicine repository (https://submit.ncbi.nlm.nih.gov/), BioProject accession number: PRJNA750937 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA750937).